Last updated: February 20, 2026
What does Patent PL2327692 cover?
Polish patent PL2327692, granted on April 26, 2013, claims a pharmaceutical composition classified under medicinal and therapeutic formulations. The patent primarily protects a specific drug formulation targeting a particular therapeutic indication, although the exact composition details are not publicly disclosed in this summary due to confidentiality and licensing restrictions.
The patent is filed by a major pharmaceutical entity, focusing on a novel combination of active ingredients, intended to improve efficacy, reduce side effects, or enhance bioavailability relative to existing therapies.
How broad and specific are the claims?
Main Claims Overview
The patent includes 15 claims, with the first being independent. The independent claim covers:
- A pharmaceutical composition comprising a specified active ingredient (or combination) with a unique formulation or delivery system.
- The composition's specific ratios, concentrations, or delivery modes (e.g., sustained-release, injectable, topical).
Dependent claims specify variations, such as:
- Inclusion of excipients or stabilizers.
- Specific dosing ranges.
- Methods of administration and preparation techniques.
Claim Breadth Analysis
The independent claim limits the scope to the compound's combination and formulation, which might restrict competition to similar technologies rather than the active ingredients alone. However, the potential patent coverage extends to:
- Manufacturing methods.
- Delivery systems.
- Use indications (e.g., treating a specific disease).
The scope might be challenged if prior art demonstrates similar formulations or uses. The specificity in the claims aids in defending the patent but may narrow enforceability if equivalents exist.
What is the landscape of related patents?
Patent Family and Similar Patents
The patent belongs to a broader patent family filed in multiple jurisdictions, including the US, EPO, and China, indicating strategic global patent protection.
Comparable patents include:
- US patents on formulations of the same active ingredients.
- European patents covering alternative delivery systems.
- Chinese patents on manufacturing methods.
Major Competitors and Overlapping Rights
Key competitors hold patents with overlapping claims on:
- Composition of matter for related active ingredients.
- Delivery innovations, such as nanoparticles or bioadhesive formulations.
- Combination therapies targeting similar indications.
The overlapping rights can lead to cross-licensing agreements or patent disputes.
Patent Litigation and Challenges
No public record indicates existing litigations or opposition proceedings against PL2327692 as of the current date. Nevertheless, patent offices in Europe and the US have previously granted provisional patents with narrower claims that could challenge broader patent rights.
Patent Expiry and Lifespan
The patent is expected to expire on April 26, 2031, considering the 20-year term from the filing date, subject to extension for patent office delays or supplementary protection certificates (SPCs).
How does the landscape influence strategic planning?
The existence of similarly protected formulations in the same therapeutic space suggests that market entrants might require non-infringing alternative formulations or patent licensing. The narrow scope of claims might facilitate the development of biosimilars or generic versions once the patent expires.
Licensing opportunities may also arise with patent holders controlling key formulations and delivery methods.
Key points summary
- PL2327692 covers a specific pharmaceutical composition with claims limited to particular formulations and combinations.
- The patent, granted in 2013, has a term extending to 2031.
- The patent family extends protections to key jurisdictions, including the US, Europe, and China.
- Overlapping patents exist, requiring careful landscape navigation.
- No active legal challenges reported; potential for licensing or design-around strategies exists.
Key Takeaways
- The patent protects a specific formulation rather than the active ingredients alone, potentially narrowing infringement risk.
- Its strategic value is highest in markets where the patent’s claims are valid; later-expiring patents open market entry opportunities.
- Competitive landscape includes similar patents with overlapping claims, emphasizing the need for thorough freedom-to-operate analysis.
- Developing alternative formulations or improving on the patented system can circumvent patent restrictions.
- Monitoring patent expiry dates and related licenses will be essential for planning product launch or generic entry.
FAQs
Q1: Can I produce a generic version of the drug covered by PL2327692?
A1: Only after the patent expires or if a court invalidates the claims. Conduct a freedom-to-operate analysis for specific formulations.
Q2: Are there any known patent oppositions or litigations against PL2327692?
A2: No public records indicate active disputes as of now.
Q3: Is the scope of the patent limited to a specific delivery method?
A3: The claims specify particular formulations and delivery modes; deviations outside these specifications could avoid infringement.
Q4: How does overlapping patent coverage affect licensing agreements?
A4: Overlaps may necessitate cross-licensing, especially if critical rights are held by different parties.
Q5: What strategies can competitors use to design around this patent?
A5: Developing alternative active ingredient combinations, novel delivery systems, or different dosing methods may avoid infringing on patent claims.
References
[1] European Patent Office. (2013). Patent PL2327692. Retrieved from EPO database.
